A Study to Assess Adverse Events and Change in Disease Activity in Participants 12 Years of Age or Older With Locally Advanced or Metastatic Solid Tumors That Harbor MET Amplification Receiving Intravenously Infused Telisotuzumab Adizutecan

A Study to Assess Adverse Events and Change in Disease Activity in Participants 12 Years of Age or Older With Locally Advanced or Metastatic Solid Tumors That Harbor MET Amplification Receiving Intravenously Infused Telisotuzumab Adizutecan is a phase 2 interventional study registered as NCT07196644 by AbbVie, with 100 participants planned, started 2025-12-01 and due to reach its primary completion in 2030-12. Interventions recorded: Telisotuzumab Adizutecan.